A monoclonal antibody with selectivity for human kappa myeloma and lymphoma cells which has potential as a therapeutic agent.
K-1-21 is a monoclonal antibody which binds to human free kappa light chains and recognises a determinant, KMA selectively expressed on kappa myeloma and lymphoma cells. KMA is absent on plasma cells and resting B cells from normal adults but can be detected on some foetal B cells and a small proportion of activated B cells. Expression of KMA is greatest on cycling cells. K-1-21 is an IgG1 antibody that elicits ADCC but will not cap the KMA determinant unless a second ligand is present. K-1-21 has potential for practical application.
D000888:Antibodies, Anti-Idiotypic / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D000920:Antibody-Dependent Cell Cytotoxicity; D000951:Antigens, Neoplasm / Q000276:immunology; D002453:Cell Cycle; D002460:Cell Line; D006801:Humans; D007145:Immunoglobulin kappa-Chains / Q000276:immunology*; D007152:Immunologic Capping; D008223:Lymphoma / Q000276:immunology*; D009101:Multiple Myeloma / Q000276:immunology*; D011947:Receptors, Antigen, B-Cell / Q000276:immunology; D008258:Waldenstrom Macroglobulinemia / Q000276:immunology*
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D007145:Immunoglobulin kappa-Chains; D011947:Receptors, Antigen, B-Cell